Chemo­Cen­tryx grabs $50M up­front, adds de­vel­op­ment part­ner­ship with Vi­for

Sev­en months af­ter Vi­for swooped in to bag the Eu­ro­pean rights to Chemo­Cen­tryx’s C5a-tar­get­ing CCX168 with an $85 mil­lion down pay­ment, the Swiss com­pa­ny has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER